These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 38874226)
1. Risks of cutaneous immune-related adverse events in long COVID: Multinational cohort studies in South Korea, Japan, and the UK. Kim H; Kyung S; Park J; Lee H; Lee M; Smith L; Rahmati M; Shin JY; Kang J; Jacob L; Papadopoulos NG; Rhee SY; Lee J; Kim HJ; Lee H; Yon DK J Med Virol; 2024 Jun; 96(6):e29740. PubMed ID: 38874226 [TBL] [Abstract][Full Text] [Related]
2. Risks of alopecia areata in long COVID: Binational population-based cohort studies from South Korea and Japan. Kyung S; Son Y; Kim M; Kang J; Smith L; Lee H; Yon DK J Med Virol; 2024 May; 96(5):e29668. PubMed ID: 38757870 [TBL] [Abstract][Full Text] [Related]
3. Incident allergic diseases in post-COVID-19 condition: multinational cohort studies from South Korea, Japan and the UK. Oh J; Lee M; Kim M; Kim HJ; Lee SW; Rhee SY; Koyanagi A; Smith L; Kim MS; Lee H; Lee J; Yon DK Nat Commun; 2024 Apr; 15(1):2830. PubMed ID: 38565542 [TBL] [Abstract][Full Text] [Related]
4. Acute and post-acute respiratory complications of SARS-CoV-2 infection: population-based cohort study in South Korea and Japan. Choi Y; Kim HJ; Park J; Lee M; Kim S; Koyanagi A; Smith L; Kim MS; Rahmati M; Lee H; Kang J; Yon DK Nat Commun; 2024 May; 15(1):4499. PubMed ID: 38802352 [TBL] [Abstract][Full Text] [Related]
5. Risk of vitiligo in patients with SARS-CoV-2 vaccination or infection: a nationwide cohort study. Kim JS; Jeong CY; Lee GJ; Yeom SW; Nam KH Eur J Dermatol; 2024 Apr; 34(2):150-157. PubMed ID: 38907545 [TBL] [Abstract][Full Text] [Related]
6. Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients. Taquet M; Sillett R; Zhu L; Mendel J; Camplisson I; Dercon Q; Harrison PJ Lancet Psychiatry; 2022 Oct; 9(10):815-827. PubMed ID: 35987197 [TBL] [Abstract][Full Text] [Related]
7. Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study. Shrotri M; Krutikov M; Palmer T; Giddings R; Azmi B; Subbarao S; Fuller C; Irwin-Singer A; Davies D; Tut G; Lopez Bernal J; Moss P; Hayward A; Copas A; Shallcross L Lancet Infect Dis; 2021 Nov; 21(11):1529-1538. PubMed ID: 34174193 [TBL] [Abstract][Full Text] [Related]
8. Cancer type and histology influence cutaneous immunotherapy toxicities: a multi-institutional cohort study. Wan G; Khattab S; Leung BW; Zhang S; Nguyen N; Tran M; Lin C; Chang C; Alexander N; Jairath R; Phillipps J; Tang K; Rajeh A; Zubiri L; Chen ST; Demehri S; Yu KH; Gusev A; Kwatra SG; LeBoeuf NR; Reynolds KL; Semenov YR Br J Dermatol; 2024 Jun; 191(1):117-124. PubMed ID: 38366637 [TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial. Akova M; Unal S Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629 [TBL] [Abstract][Full Text] [Related]
10. Antibody levels following vaccination against SARS-CoV-2: associations with post-vaccination infection and risk factors in two UK longitudinal studies. Cheetham NJ; Kibble M; Wong A; Silverwood RJ; Knuppel A; Williams DM; Hamilton OKL; Lee PH; Bridger Staatz C; Di Gessa G; Zhu J; Katikireddi SV; Ploubidis GB; Thompson EJ; Bowyer RCE; Zhang X; Abbasian G; Garcia MP; Hart D; Seow J; Graham C; Kouphou N; Acors S; Malim MH; Mitchell RE; Northstone K; Major-Smith D; Matthews S; Breeze T; Crawford M; Molloy L; Kwong ASF; Doores K; Chaturvedi N; Duncan EL; Timpson NJ; Steves CJ Elife; 2023 Jan; 12():. PubMed ID: 36692910 [TBL] [Abstract][Full Text] [Related]
11. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. Antonelli M; Penfold RS; Merino J; Sudre CH; Molteni E; Berry S; Canas LS; Graham MS; Klaser K; Modat M; Murray B; Kerfoot E; Chen L; Deng J; Österdahl MF; Cheetham NJ; Drew DA; Nguyen LH; Pujol JC; Hu C; Selvachandran S; Polidori L; May A; Wolf J; Chan AT; Hammers A; Duncan EL; Spector TD; Ourselin S; Steves CJ Lancet Infect Dis; 2022 Jan; 22(1):43-55. PubMed ID: 34480857 [TBL] [Abstract][Full Text] [Related]
12. Prior COVID-19 vaccination and reduced risk of cerebrovascular diseases among COVID-19 survivors. Chen SY; Hsieh TYJ; Hung YM; Oh JW; Chen SK; Wang SI; Chang R; Wei JC J Med Virol; 2024 May; 96(5):e29648. PubMed ID: 38727032 [TBL] [Abstract][Full Text] [Related]
13. Long-Term Autoimmune Inflammatory Rheumatic Outcomes of COVID-19 : A Binational Cohort Study. Kim MS; Lee H; Lee SW; Kwon R; Rhee SY; Lee JA; Koyanagi A; Smith L; Fond G; Boyer L; Lee J; Rahmati M; Shin JY; Min C; Shin JI; Yon DK Ann Intern Med; 2024 Mar; 177(3):291-302. PubMed ID: 38437702 [TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 vaccine effectiveness and clinical outcomes in hemodialysis patients: the NHIS-COVID-19 cohort study in South Korea. Lee YK; Jeong SA; Park HC; Kim DH; Yoo KD; Yoon HE; Kim YG; Cho A Front Public Health; 2024; 12():1372525. PubMed ID: 38784571 [TBL] [Abstract][Full Text] [Related]
15. Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Therapy. Tang K; Seo J; Tiu BC; Le TK; Pahalyants V; Raval NS; Ugwu-Dike PO; Zubiri L; Naranbhai V; Carrington M; Gusev A; Reynolds KL; LeBoeuf NR; Asgari MM; Kwatra SG; Semenov YR JAMA Dermatol; 2022 Feb; 158(2):189-193. PubMed ID: 35019948 [TBL] [Abstract][Full Text] [Related]
16. Associations of BMI with COVID-19 vaccine uptake, vaccine effectiveness, and risk of severe COVID-19 outcomes after vaccination in England: a population-based cohort study. Piernas C; Patone M; Astbury NM; Gao M; Sheikh A; Khunti K; Shankar-Hari M; Dixon S; Coupland C; Aveyard P; Hippisley-Cox J; Jebb SA Lancet Diabetes Endocrinol; 2022 Aug; 10(8):571-580. PubMed ID: 35780805 [TBL] [Abstract][Full Text] [Related]
17. Vaccination and the risk of post-acute sequelae after COVID-19 in the Omicron-predominant period. Huh K; Kim YE; Bae GH; Moon JY; Kang JM; Lee J; Bae JW; Peck KR; Jung J Clin Microbiol Infect; 2024 May; 30(5):666-673. PubMed ID: 38331252 [TBL] [Abstract][Full Text] [Related]
18. COVID-19 vaccination and leprosy-A UK hospital-based retrospective cohort study. de Barros B; Pierce R; Sprenger C; Ong ELH; Walker SL PLoS Negl Trop Dis; 2023 Aug; 17(8):e0011493. PubMed ID: 37540711 [TBL] [Abstract][Full Text] [Related]
19. Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden. Nordström P; Ballin M; Nordström A Lancet Infect Dis; 2022 Jun; 22(6):781-790. PubMed ID: 35366962 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Emary KRW; Golubchik T; Aley PK; Ariani CV; Angus B; Bibi S; Blane B; Bonsall D; Cicconi P; Charlton S; Clutterbuck EA; Collins AM; Cox T; Darton TC; Dold C; Douglas AD; Duncan CJA; Ewer KJ; Flaxman AL; Faust SN; Ferreira DM; Feng S; Finn A; Folegatti PM; Fuskova M; Galiza E; Goodman AL; Green CM; Green CA; Greenland M; Hallis B; Heath PT; Hay J; Hill HC; Jenkin D; Kerridge S; Lazarus R; Libri V; Lillie PJ; Ludden C; Marchevsky NG; Minassian AM; McGregor AC; Mujadidi YF; Phillips DJ; Plested E; Pollock KM; Robinson H; Smith A; Song R; Snape MD; Sutherland RK; Thomson EC; Toshner M; Turner DPJ; Vekemans J; Villafana TL; Williams CJ; Hill AVS; Lambe T; Gilbert SC; Voysey M; Ramasamy MN; Pollard AJ; ; ; Lancet; 2021 Apr; 397(10282):1351-1362. PubMed ID: 33798499 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]